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Abstract 
Objective HbA1c levels are increasingly measured in screening for diabetes; we 
investigated whether HbA1c may simultaneously improve CVD risk assessment, 
using QRISK3, ACC/AHA and SCORE scoring systems. 
Research Design and Methods UK Biobank participants without baseline CVD or 
known diabetes (n=358,275) were included. Associations of HbA1c with CVD was 
assessed using Cox models adjusting for classical risk factors. Predictive utility was 
determined by the C-index and net reclassification index (NRI). A separate analysis 
was conducted in 16,619 participants with known baseline diabetes. 
Results Incident fatal or non-fatal CVD, as defined in the QRISK3 prediction model, 
occurred in 12,894 participants over 8.9 years. 3.3% (n=11,680) of participants had 
prediabetes (42.0-47.9mmol/mol (6.0 to 6.4%) and 0.7% (n=2579) undiagnosed 
diabetes (≥48.0mmol/mol;≥ 6.5%). In unadjusted models, compared with the 
reference group (<42.0 mmol/mol; <6.0%), those with prediabetes and undiagnosed 
diabetes were at higher CVD risk: HR 1.83 (95% CI 1.69-1.97) and 2.26 (95% CI 
1.97-2.61), respectively. After adjustment for classical risk factors, these attenuated 
to HR 1.11 (95% CI 1.03-1.20) and 1.20 (1.04-1.38), respectively. Adding HbA1c to 
the QRISK3 CVD risk prediction model (C-index 0.7387) yielded a small 
improvement in discrimination (C-index +0.0004, 95% CI 0.0001, 0.0007). The NRI 
showed no improvement. Results were similar for models based on the ACC/AHA 
and SCORE risk models. 
Conclusion The near two-fold higher unadjusted risk for CVD in prediabetes is 
driven mainly by abnormal levels of conventional CVD risk factors. Whilst HbA1c 
adds minimally to CV risk prediction, those with pre-diabetes should have their 
conventional CV risk factors appropriately measured and managed.   
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Introduction 
Circulating hemoglobin A1c (HbA1c) indicates average blood glucose concentrations 
over the preceding 3 months. The absence of the need for patients to fast for HbA1c 
assessment is a major advantage of measuring HbA1c for screening for 
dysglycemia, including diabetes and pre-diabetes, and has been endorsed for such 
by society recommendations (1). Whether screening HbA1c values incrementally 
contribute to cardiovascular disease (CVD) risk assessment and prognostication 
beyond established risk predictors in patients without diabetes remains uncertain, 
with meta-analysis of observational data suggesting independent prognostic utility of 
HbA1c (2).  
 
The European Systematic Coronary Risk Estimation (SCORE) CVD risk score (3), 
QRISK3 risk score (4), and the ACC/AHA CVD risk score (5) currently do not include 
any specific measure of glycemia in their risk prediction models, and include only 
diabetes as a categorical entity. In support of this approach, an individual participant 
meta-analysis of nearly 300,000 participants without diabetes or known CVD at 
baseline suggested that HbA1c added very modest discriminative ability to CVD risk 
estimation methods that use conventional risk factors (6). Moreover, some data 
suggest that individuals with prediabetes are at significantly elevated CVD risk due in 
part to their modestly raised glycemia levels (7,8). However, such work has been 
based on either relatively small single cohorts or multiple cohorts with considerable 
inter-study heterogeneity. The lack of data from a single large cohort with consistent 
phenotyping of exposures and events is a limitation in interpreting the existing 
literature on this topic. Since increasing numbers of people are being screened for 
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diabetes using HbA1c measurement, this question needs better evidence to inform 
clinical care.  
 
Capitalizing on the availability of data in the UK Biobank comprising several hundred 
thousand participants including baseline HbA1c measures and capture of 
longitudinal clinical outcomes, the CVD prognostic utility of HbA1c was examined in 
participants without prevalent diabetes.  
 
Methods 
The UK Biobank recruited 502,617 participants (aged 37 to 73) from 22 assessment 
centres across the UK between April 2007 and December 2010. Baseline biological 
measurements were recorded and touch-screen questionnaires were administered, 
as described elsewhere (9,10). The UK Biobank received ethical approval from the 
North West Multi-centre Research Ethics Committee (REC reference: 
11/NW/03820). All participants gave written informed consent before enrolment in 
the study, which was conducted in accord with the principles of the Declaration of 
Helsinki. 
 
Systolic and diastolic blood pressure was taken as the first baseline measurement, 
preferentially using an automated measurement. Smoking status was categorised 
into never or former/current smoking. Ethnicity was coded as white, black, South 
Asian, or mixed/other, with white as the referent group. Blood collection sampling 
procedures for the study have been previously described and validated (11). 
Biochemistry measures were performed at a dedicated central laboratory on around 
480,000 samples between 2014 and 2017. These included serum total cholesterol 
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(TC) and HDL cholesterol (Beckman Coulter AU5400) and plasma glycated 
hemoglobin (HbA1c, Bio-Rad VARIANT II Turbo). Data were adjusted by UK 
Biobank centrally before release to adjust for pre-analytical variables. Further details 
of these measurements, and of the data adjustments, can be found in the UK 
Biobank online showcase and protocol (http://www.ukbiobank.ac.uk and 
https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/biomarker_issues.pdf).  
 
The definition of baseline diabetes included self-reported type 1 or type 2 diabetes, 
and those who reported using insulin. Statin and blood pressure medication use 
were also recorded from self-report. Baseline cardiovascular disease was defined as 
self-reported prior myocardial infarction, stroke, transient ischemic attack as well as 
hospital diagnoses including ICD10 codes I20-24, I63-64, G45.  
 
Date and cause of death were obtained from death certificates held by the National 
Health Service (NHS) Information Centre for participants from England and Wales, 
and the NHS Central Register Scotland for participants from Scotland. The main 
outcome of interest in the present study reflected the outcome used in the QRISK3 
risk score (4), namely fatal or non-fatal coronary heart disease, ischemic stroke or 
transient ischemic attack (ICD-10 G45, I20-24, I63-64) (hereafter QRISK3 CVD 
events). There were two additional outcomes of interest in the present study: 1) a 
composite of fatal and non-fatal cardiovascular disease that reflects the ACC/AHA 
guidelines prediction score including death from cardiovascular disease (ICD-10 I20-
25, I60-64) or hospitalisation for cardiovascular disease (ICD-10 I21, I22, I60-64)(5) 
(hereafter ACC/AHA CVD events); 2) fatal cardiovascular disease as defined by 
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primary cause of death from events included in the European SCORE clinical 
guidelines (I10-15, I44-51, I20-25, I61-73) (12) (hereafter SCORE CVD events).  
 
End of follow-up for each participant was recorded as the date of death or the date of 
end of follow-up for the assessment centre attended (31st January 2018 for 
participants in England or Wales, and 30th November 2016 for participants in 
Scotland), or the first date of CVD-related hospitalisation (for both composite 
fatal/non-fatal outcomes), whichever came first. The period at risk per participant 
began on the date of their assessment. Participants with baseline CVD were 
excluded from all analyses, and those with baseline diabetes were analysed 
separately from the main cohort. 
 
Statistical analyses 
Log transformed HbA1c was analysed as a continuous variable and was categorised 
using thresholds of <42.0mmol/mol (<6.0%) (normal/referent), 42.0-47.9mmol/mol 
(6.0-6.4%) (prediabetes), and ≥48.0mmol/mol (≥6.5%) (undiagnosed diabetes), as 
well as deciles of the distribution. Classical CVD risk factors were expressed as 
mean (standard deviation) if symmetrically distributed, median (interquartile range) if 
skewed, and number (%) if categorical. The prediabetes category of HbA1c was 
further split into the following categories to examine its relationship with CVD 
outcomes: 42.0-44.9mmol/mol (6.0-6.2%), and 45.0-47.9mmol/mol (6.3-6.4%). The 
distribution of classical CVD risk factors by categories of HbA1c was assessed using 
ANOVA, a Wilcoxon test for trend, or a chi-squared test, respectively. Associations 
between classical CVD risk factors and HbA1c with CVD outcomes of interest were 
also tabulated using these methods.  
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Univariable associations of categories of HbA1c with outcomes of interest were 
initially explored using Kaplan-Meier methods. Associations of continuous and 
categorical HbA1c with outcomes of interest were investigated using Cox-
proportional hazard models for each outcome (adjusted for age, sex, ethnicity, total 
and HDL cholesterol, SBP, DBP, antihypertensive medications, smoking, and statin 
use in ACC/AHA or SCORE risk scores where for QRISK3, adjusted for age, 
ethnicity, Townsend deprivation index (index of deprivation based on postcode), 
total:HDL cholesterol, BMI, family history of CVD, hypertension, rheumatoid arthritis, 
atrial fibrillation, chronic kidney disease stages 3-5, migraine, steroid use, systemic 
lupus erythematosus, atypical antipsychotic medication use, serious psychological 
disorders, antihypertensive medications, erectile dysfunction), and also using 
restricted cubic splines to explore the shape of the association (data not shown). The 
proportional hazard assumption was checked by inspection of Schöenfeld residuals. 
Tests for interaction were performed by categories of the main covariates of interest.  
 
The ability of HbA1c to improve prediction of CVD was tested for the outcomes of 
interest, using the specific established risk factors for each risk score for the relevant 
outcomes; the ACC/AHA (adjusting as above) models for composite fatal and non-
fatal CVD, and the SCORE European model for fatal CVD (adjusting as above for 
fatal CVD outcome). All models excluded participants with baseline CVD. 
Improvement in prediction was tested using Harrell’s C-Index for survival data, 
testing for increased concordance on the addition of HbA1c to the model. We used a 
continuous net reclassification index (NRI) to investigate changes in predicted risk 
classification on addition of HbA1c to the models. The continuous NRI is based on 
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improvements in classification across integer % risk thresholds, thus avoiding 
arbitrary decisions about defining clinically relevant risk categories (13). Four 
sensitivity analyses were conducted. Discrimination ability after addition of HbA1c 
was also tested: 1) after exclusion of participants with HbA1c>48.0mmol/mol, i.e. 
undiagnosed diabetes; 2) after exclusion of participants on statins; and 3) after 
exclusion of participants with self-reported diabetes and those with HbA1c>48.0 
mmol/mol. We also compared CVD risk within the prediabetes category by splitting 
this group into those with levels of 42-44 (6.0-6.2%) and 45-47 mmol/mol (6.3-6.4%).  
 
All analyses were performed using STATA 14 (StataCorp LP) and R. A 2-sided p 
value of 0.05 was considered statistically significant without adjustment for multiple 
comparisons.  
 
Role of the funding source 
The funder played no role in developing the analysis plan, conducting the analysis, 
or writing of the manuscript. 
 
Results 
Cross sectional associations 
Of 438,548 people without baseline CVD included in the study, complete data on 
covariates, including HbA1c were available in 374,894 (76%) participants, and after 
exclusion of participants with known/self-reported diabetes (n=16, 619), the cohort 
for the main analyses included 358,275 participants, including those with HbA1c 
≥48.0 mmol/mol (≥6.5%) without report of prior diabetes diagnosis (i.e. undiagnosed 
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diabetes). Median HbA1c in this cohort was 34.9mmol/mol (5.3%) (Q1-Q3 32.5-
37.3mmol/mol (5.1-5.6%)). 
 
Participants with prediabetes were slightly older, and had a poorer CVD risk profile 
as they were more likely to be current smokers, had higher SBP by more than 6 
mmHg, higher BMI by more than 3 kg/m2, and higher total cholesterol to HDL-C ratio 
driven by lower HDL-C (Table 1). They were also more likely to be of non-white and 
take blood pressure lowering medications or statins (Table 1). The higher 
prevalence of other CVD risk factors was even more marked for those with 
undiagnosed diabetes, particularly for BMI and SBP and HDL-C (Table 1). 
 
CVD outcomes 
In the main cohort without known baseline diabetes, median follow up time for the 
QRISK3-based fatal/non-fatal CVD outcome was 8.9 years (Q1-Q3 8.2-9.4). The 
fatal/non-fatal CVD outcome occurred in 12,894 participants (3.6%), ACC/AHA-
based CVD outcomes occurred in 6618 participants (1.9%), and SCORE-based fatal 
CVD occurred in 1813 participants (0.5%). In the main cohort without known 
baseline diabetes, HbA1c was on average 1.2 mmol/mol higher in participants who 
subsequently had an incident CVD event (35.1 versus 36.2 mmol/mol in those 
without versus with incident CVD, a difference of 1.2 mmol/mol, 95% CI 1.1-1.3). In 
people with known baseline diabetes (n=16, 619), over a median of 8.7 years follow 
up, the QRISK-3 based CVD outcome occurred in 1475 (8.9%) of participants, and 
fatal CVD occurred in 308 (1.9%).  
 
Association of HbA1c with CVD outcomes 
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The unadjusted risk of the composite fatal/non-fatal CVD outcome was greatest for 
participants with known diabetes but was also higher in those with undiagnosed 
baseline diabetes and in those with prediabetes (Figure 1). Those with prediabetes 
were at 1.83 (95% CI 1.69-1.97) fold higher risk of CVD compared with those with 
normal HbA1c, and those with undiagnosed diabetes were at 2.26 (95% CI 1.97-
2.61) higher risk (Table 2).  
 
Figure 2 shows the unadjusted and adjusted risks associated with HbA1c across the 
range from normal to pre-diabetes, undiagnosed diabetes and prevalent diabetes. 
The results, as also noted in Table 2, show that the CVD risks in the pre-diabetes 
range were substantially attenuated with adjustment for usual CVD risk factors such 
that the HRs were rather modest. Whilst adjustment also attenuates the HR in the 
undiagnosed and diabetes groups, adjusted relative risks remained statistically 
significant. The association between HbA1c and the ACC/AHA outcome was broadly 
similar, but adjusted hazard ratios for the association between HbA1c and fatal 
(SCORE) CVD were larger in the undiagnosed diabetes group (Table 2).  
 
When the CVD association between HbA1c and CVD was analysed separately in the 
split pre-diabetes groups (42.0-44.9 mmol/mol (6.0-6.2%) and 45.0-47.9 mmol/mol 
(6.3-6.4%), hazard ratios were similar and had overlapping confidence intervals 
(1.11, 95% CI 1.02-1.21, and 1.11, 95% CI 0.95-1.29, respectively).  
 
HbA1c and prediction of CVD outcomes in addition to classical risk factors 
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Using models accounting for classical CVD risk factors, individuals with normal 
glycemia had a median 10-year CVD risk of 2.7% for QRISK3 CVD, 1.4% for 
ACC/AHA CVD, and 0.4% for fatal SCORE CVD.  
 
In a model of CVD prediction based on the QRISK3 CVD outcome among 
participants without self-reported diabetes at baseline, classical CVD risk factors 
yielded a C-index of 0.7392 (95% CI 0.7353-0.7431), which was slightly increased 
upon addition of log HbA1c (C-index change +0.0004, 95% CI 0.0001-0.0007). In 
those with a baseline HbA1c<48.0mmol/mol (<6.5%), modelling using classical CVD 
risk factors yielded a C-index of 0.7391 (95% CI 0.7352-0.741), which was also 
modestly improved upon addition of log HbA1c (C-index change +0.0003, 95% CI 
0.0001-0.0006).  
 
Patterns were similar for the other outcomes of interest. In a model of ACC/AHA 
CVD, modelling using classical CVD risk factors yielded a C-index of 0.7360 (95% CI 
0.7304-0.7416). Addition of log HbA1c to the ACC/AHA model also modestly 
improved discrimination in participants with known diabetes mellitus (C-index + 
0.0007, 95% CI 0.0001-0.0012). In models of fatal CVD based on the SCORE fatal 
CVD outcome, modelling using classical CVD risk factors yielded a C-index of 
0.7653 (95%CI 0.7548-0.7759), and addition of log HbA1c improved discrimination 
modestly (C-index +0.0025, 95% CI 0.0005-0.0045). For the net reclassification 
index, no significant reclassification was noted upon addition of HbA1c, in either 
cases (i.e. those with an outcome) or non-cases in any model (Table 3). These 
results were similar when participants with HbA1c ≥48mmol/mol (≥6.5%) were 
excluded. 
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Discussion 
In this large cohort of over 370,000 individuals, we confirm that HbA1c is broadly 
linearly related to CVD risk in unadjusted analyses, but that this association is 
substantially attenuated with adjustment for conventional CVD risk factors. Indeed, in 
those with prediabetes, whilst their unadjusted HR for CVD risk was 1.83 relative to 
those with normal HbA1c, this fell to just 1.11 when adjusting for usual CVD risk 
factors. This means that whilst people with prediabetes are, on average, have 
around an 80% greater CVD risk compared with those with normal HbA1c levels, 
such risk is not largely driven by elevated HbA1c per se, but rather by differences in 
the prevalence or levels of other established CVD risk factors: age, blood pressure, 
smoking, lipid levels, and BMI. Furthermore, we show that addition of HbA1c when 
the conventional risk factors are already accounted for does not meaningfully 
improve CVD risk prediction, as shown by no gain in the NRI, a measure of risk 
improvement. In contrast, the risk of CVD was meaningfully higher in those with 
known or undiagnosed baseline diabetes, supporting the diagnostic cut-off for HbA1c 
as it relates to CVD risk.  
 
Our results add to existing literature by validating prior results published by the 
ERFC that demonstrated that whilst HbA1c levels better predicted incident CVD 
events than fasting and post prandial glucose levels in those without prior diabetes 
or CVD, the added predictive gain from inclusion of HbA1c in risk prediction was 
modest. The importance of repeating this work cannot be underestimated for several 
reasons. First, ERFC data used individual HbA1c data from multiple cohorts with a 
wide variety of HbA1c measurement techniques. Second, assays for HbA1c have 
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improved since the early 2000s with better reproducibility and our results are based 
on one assay used in the entire cohort, thereby limiting inter-assay variation. Finally, 
we were able to compare results in those categorised using a modern definition of 
prediabetes, as accepted by the National Institute for Health and Care Excellence 
(NICE) and criteria used in other European countries, and as such inform clinical 
practice. Splitting this category into lower and higher HbA1c (42-44mmol/mol (6.0-
6.2%), or 45-47 mmol/mol (6.3-6.4%)) revealed near identical point estimates and 
overlapping confidence intervals between the two groups. Therefore, despite the 
breadth of HbA1c values observed and potential differential risk categories, it 
appears appropriate to retain the present boundaries in particular for diabetes 
diagnosis at 6.5% (or 48 mmol/mol), at least on the basis of CVD risk. Of course, the 
glycemia thresholds to diagnose diabetes have been determined on the basis of risk 
for retinopathy, but it is interesting that they seem appropriate for macrovascular 
disease.  
 
Our results have practical implications for clinical practice. First, these data are 
broadly supportive that HbA1c should be used to diagnose prediabetes and new 
diabetes, but also show that it is unlikely to be meaningfully additive for CVD risk 
prognostication in those without known diabetes. Second, all those found to have 
prediabetes on the basis of HbA1c levels should have their CVD risk assessed by 
conventional methods, i.e. with additional measurement of lipids and blood pressure, 
as currently recommended (14) and it would not be appropriate to give only lifestyle 
advice to prevent or delay diabetes. Rather, as those with prediabetes had higher 
baseline CVD risk, with meaningfully higher mean SBP at just under 146 mmHg, 
mean BMI just over 30 kg/m2, and higher average cholesterol to HDL-C ratios, they 
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need comprehensive CVD risk management. Finally, given modest numbers with 
prediabetes or undiagnosed diabetes (<4% of cohort in total), the value of using a 
non-lab based score first to identify those at highest risk for diabetes is reaffirmed 
such that HbA1c should be added only to those with a high non-lab based risk score, 
as has been proposed by NICE (15). We do, however, recognise that UK Biobank is 
not nationally representative but even so, the relatively modest numbers with 
prediabetes and undiagnosed diabetes is noteworthy.  
 
As with any study, our work has strengths and limitations. The present study is 
among the largest single cohort reported to date to measure HbA1c and assess CVD 
risk, with standardised measurements across the cohort. The limitations stem, as 
noted above, from UK Biobank cohort characteristics that are somewhat healthier 
than the average UK population. They also arise from lack of other glycemia 
measures due to the non-fasting nature of the baseline measurements in many, 
although ERFC data have shown HbA1c is more strongly linked to CVD than fasting 
or 2-hour glucose. Due to limited power, we were also unable to examine whether 
associations of HbA1c to outcomes were different by ethnicity..  
 
In conclusion, in this very large well phenotyped cohort with central lab assessment 
of HbA1c, we show that HbA1c minimally improves CVD risk prediction in patients 
without diabetes. The same is also true for the subset with prediabetes. The near 
two-fold higher unadjusted risk for CVD in prediabetes is driven mainly by abnormal 
levels of conventional CVD risk factors. As such, and as recommended (14), this 
group would benefit from lifestyle advice to prevent diabetes, and from all 
conventional CVD risk factors being assessed and, where relevant, treated.  
17 
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Table 1. Distribution of classical cardiovascular disease risk factors across categories of HbA1c in 
those without known diabetes. 
 HbA1c category  
 
<42.0mmol/mol 
(<6.0%) 
Normal 
42.0-47.9mmol/mol 
(6.0-6.4%) 
Prediabetes 
≥48mmol/mol  
(≥6.5%) 
Undiagnosed diabetes 
P-value 
N, percent (n=344,016, 96.0%) (n=11,680, 3.3%) (n=2579, 0.7%)  
Age (years) 55.94 (8.10) 59.65 (6.94) 57.91 (7.47) <0.001 
Sex (%)     
Women 192435 (55.9%) 6395 (54.8%) 1060 (41.1%) <0.001 
Men 151581 (44.1%) 5285 (45.2%) 1519 (58.9%)  
Ethnicity (%)     
White 329593 (95.8%) 10108 (86.5%) 2143 (83.1%) <0.001 
Black 3795 (1.1%) 586 (5.0%) 134 (5.2%)  
South Asian 4058 (1.2%) 463 (4.0%) 172 (6.7%)  
Other 6570 (1.9%) 523 (4.5%) 130 (5.0%)  
Smoker      
No 309000 (89.8%) 9792 (83.8%) 2205 (85.5%) <0.001 
Yes 35016 (10.2%) 1888 (16.2%) 374 (14.5%)  
Systolic blood 
pressure (mmHg)   139.31 (19.63) 145.92 (19.61) 149.50 (19.40) <0.001 
Diastolic blood 
pressure (mmHg) 82.35 (10.66) 84.89 (10.62) 88.14 (10.74) <0.001 
BMI (kg/m2) 26.99 (4.47) 30.17 (5.57) 32.01 (5.72) <0.001 
BP medication (%) 52909 (15.4%) 3724 (31.9%) 722 (28.0%) <0.001 
Statins (%) 32229 (9.4%) 2774 (23.8%) 494 (19.2%) <0.001 
Total cholesterol 5.82 (1.08) 5.81 (1.18) 5.89 (1.24) 0.007 
HDL cholesterol 1.48 (0.38) 1.33 (0.33) 1.20 (0.29) <0.001 
Total : HDL 
cholesterol  4.14 (1.11) 4.57 (1.20) 5.08 (1.25) <0.001 
BMI body mass index; BP blood pressure; HDL high-density lipoprotein; SD standard deviation. 
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Table 2. Association of different glycemia categories with risk of composite fatal/non-fatal CVD outcomes in unadjusted and adjusted models based on all 
three risk scoring systems, using a complete case analysis.  
 QRISK3 ACC/AHA SCORE 
N participants  
(n CVD events) 
 
357833  
(12894) 
357833  
(6618) 
357833  
(1813) 
 Unadjusted HR Adjusted  
HR 
Unadjusted HR Adjusted  
HR 
Unadjusted 
HR 
Adjusted  
HR 
HbA1c categories       
Referent - normal <42.0mmol/mol (<6.0%) 1 1 1 1 1 1 
Prediabetes 42.0-47.9mmol/mol (6.0 to 
6.4%) 
1.83 
 (1.69-1.97) 
1.11 
 (1.03-1.20) 
1.81  
(1.63-2.01) 
1.19  
(1.07-1.32) 
2.49  
(2.09-2.96) 
1.10 
(1.09-1.10) 
Undiagnosed diabetes ≥48.0mmol/mol 
(≥6.5%) 
2.26  
(1.97 – 2.61) 
1.20  
(1.04-1.38) 
2.42  
(2.00-2.92) 
1.42  
(1.17-1.72) 
2.89  
(2.07-4.04) 
2.37 
(2.13-2.65) 
Models adjusted according to outcome (see text for covariate lists).
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Table 3. Improvement in net classification (net reclassification index) across a binary 10-year risk threshold upon addition of HbA1c to a range of CVD 
outcomes in 357833 participants without known baseline diabetes and with complete data for all covariates. 
Model Comparator Addition Binary risk 
threshold for 
high/low 10 year 
risk 
Overall NRI 
(95% CI) 
Case NRI 
(95%CI) 
Non-case NRI 
(95% CI) 
QRISK3 QRISK3 
classical CVD 
risk factors * 
+HbA1C 10% 0.01%  
(-0.01, 0.03) 
0.01%  
(0.00, 0.04%) 
-0.01%  
(-0.01, 0.00) 
ACC/AHA** ACC/AHA 
classical CVD 
risk factors** 
+HbA1C 7.5% -0.11%  
(-0.49, 0.22%) 
-0.09%  
(-0.47, 0.24%) 
-0.02%  
(-0.04, 0.00%) 
SCORE SCORE 
classical CVD 
risk factors*** 
+HbA1C 5% 0.28%  
(-0.33, 0.87%) 
0.29%  
(-0.32, 0.88%) 
-0.01%  
(-0.02, 0.00%) 
*QRISK3 outcomes and broad risk factors (age, sex, nine category ethnicity, Townsend deprivation index, total:HDL cholesterol, SBP, BMI, family history of 
CVD, diabetes, hypertension, rheumatoid arthritis, atrial fibrillation, chronic kidney disease stages 3-5, migraine, steroid use, systemic lupus erythematosus, 
atypical antipsychotic medication use, serious psychological disorders, antihypertensive medications, erectile dysfunction, smoking and statin use. 
** ACC/AHA outcomes and broad risk factors (age, sex, four category ethnicity, total cholesterol, HDL cholesterol, systolic and diastolic blood pressure, blood 
pressure medication, smoking, statin use). 
*** SCORE outcomes and broad risk factors (age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, smoking). 
  
25 
 
Figure 1. Unadjusted and adjusted (for QRISK3 risk factors) hazard ratios of composite fatal/non-fatal CVD by deciles of baseline HbA1c in those without 
baseline diabetes (n=355,696) and in participants with undiagnosed diabetes (n=2579) or known baseline diabetes (n= 16,619).  For simplicity, categories are 
depicted only as mmol/mol. The dashed line represents ≥ 48 mmol/mol (6.5%).   
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